Form 424B5 Viridian Therapeutics,
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Viridian Therapeutic (VRDN) PT Raised to $44 at RBC Capital
September 13, 2024 6:33 AM EDTRBC Capital analyst Gregory Renza raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $44.00 (from $35.00) while maintaining a Outperform rating.
The analyst comments "This week's pivotal ph.III THRIVE topline for veligrotug (Veli'; VRDN-001 IV) in active TED came in as a... More
